This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a prospective randomised controlled trial that was carried out in 12 sites. The sites included 2 visiting nurse associations, 6 hospitals and 4 health centres. The sites were paired on the basis of type of site and the demographic characteristics of the provider's target population (e.g. rural versus urban). Then, the two members of each matched pair were randomly assigned to one of the two interventions. The unit of randomisation was the site. The length of follow-up was 12 months. Approximately 72% of the MI women and 80% of the EI women completed the baseline and follow-up screenings.
Analysis of effectiveness
Only patients whose data were available at follow-up assessment were considered in the analysis of effectiveness (per protocol analysis). The primary health outcomes were the changes in unadjusted means for risk factors subsequently used in the decision model (total and HDL cholesterol, systolic and diastolic blood pressure, age, diagnosis of diabetes and status of current smoker). Comparability of the study groups at baseline was not discussed.
Effectiveness results
The changes in the unadjusted means (unit of measurement not reported) were: for systolic blood pressure, from 132.5 (+/-18.9) to 128.7 (+/-18.2) in the MI group and from 136 (+/-21) to 131.4 (+/-18.1) in the EI group; for diastolic blood pressure, from 78.14 (+/-9.9) to 76.6 (+/-9.7) in the MI group and from 80.8 (+/-10.6) to 79.3 (+/-9.6) in the EI group; for age, from 59 (+/-7.4) to 59.9 (+/-7.2) in the MI group and from 59 (+/-7) to 59.9 (+/-7) in the EI group ; from 6.6 to 8% (MI group) and from 9.1 to 9.3% (EI group) for the percentage of those with a diagnosis of diabetes; and from 18.3 to 15.2% (MI group) and from 21.1 to 17.4% (EI group) for the percentage of those with the status of current smoker.
Clinical conclusions
The effectiveness data estimated in the study were used as inputs in the analytic model.
Modelling
A developed model (see Other Publications of Related Interest) was used to predict the 10-year probability of coronary heart disease (CHD) such as angina pectoris, myocardial infarction, coronary insufficiency and CHD death. The approach used a scoring methodology to assign points to risk factors such as age, total and HDL cholesterol, hypertension, smoking status and diabetes status.
Measure of benefits used in the economic analysis
The summary benefit measure was the change in the average 10-year probability of CHD. This was derived from the analytic model. An annual discount rate of 3% was applied. The consequent increase in life expectancy was also calculated. A regression analysis approach was used to calculate the change in the 10-year probability of CHD.
Direct costs
Discounting was not applied since the costs were incurred during one year. The unit costs and the quantities of resources used were not presented separately. The health services included in the economic evaluation were grouped into four main categories. More specifically, outreach and follow-up, CVD screening, EI activities (EI group only), and administrative duties. Both labour and materials components were considered for each category. The initial cost of the programme was excluded, as were Massachusetts Department of Public Health staff costs. The cost/resource boundary of the study was not reported. Resource use was estimated using actual data derived from the sample of women included in the effectiveness study. The price year and the source of the cost data were not reported.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency

US dollars ($).
Sensitivity analysis
Sensitivity analyses were not carried out.
Estimated benefits used in the economic analysis
The average 10-year probability of CHD changed from 9.4 to 9.2% in the MI group (difference -0.2%), and from 10.3 to 9.8% in the EI group (difference -0.5%). The difference between the changes in the two groups did not reach statistical significance. Therefore, the two interventions were considered equally effective in reducing the 10-year probability of CHD.
The discounted increase in life expectancy was 0.038 in a 59-year old woman, 0.020 in a 69-year-old woman, 0.002 in a 79-year-old woman, and 0 in both 89-and 95-year-old women.
Cost results
The average total per capita cost was $487 in the MI site and $603 in the EI site. If only administrative and EI programme costs were considered, the EI strategy led to an incremental cost of $191 in comparison with the MI intervention.
Synthesis of costs and benefits
An incremental cost-effectiveness ratio was calculated to combine the costs and benefits of the two alternative strategies. The incremental cost to achieve a 1 percentage point larger decrease in the 10-year probability of CHD with
